Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, SCZ

Orig3n Announces Comprehensive Solution To Enable COVID-19 Testing Of Massachusetts Nursing Home Residents

BOSTON, May 12, 2020 /PRNewswire/ -- Orig3n, Inc., a Boston-based company pioneering the future of wellness and health through genetics and biotechnology, has announced a comprehensive solution to enable COVID-19 testing for Massachusetts nursing home residents.

Orig3n is offering the Orig3n 2019 Novel Coronavirus (COVID-19) Test under an Emergency Use Authorization (EUA) from FDA to authorized healthcare providers and institutions nationwide. The test detects the presence of nucleic acid from the virus that causes COVID-19 and is for use with patients suspected of having contracted COVID-19 (subject to current guidance for administration of tests in order to evaluate infection).

"While our nursing homes, employers, cities and towns are in great need of testing, they face the greatest challenges in coordinating multiple suppliers and service providers to provide testing on the scale that is needed," said Robin Y. Smith, President and CEO of Orig3n.  "Orig3n offers a single, seamless, end-to-end solution that incorporates specimen collection swabs, healthcare providers to collect specimens, logistics of transporting the specimens back to the laboratory, and testing in our Boston-based high complexity clinical laboratory.  We believe this program will help solve many of the obstacles that are currently preventing the widespread testing that we so desperately need. Orig3n is incredibly excited to offer this solution to our state's nursing homes in service of their residents, many of whom are at high-risk.  Orig3n's approach provides a model for the entire nation to make comprehensive testing happen." 

Orig3n seeks to be the partner of choice for coordinating and providing COVID-19 testing for defined populations.  The nursing home program is one of many applications for Orig3n's fully-integrated solution, including:

"As states and municipalities consider ways to get back to 'normal,' we see multiple phases to this process," said Mr. Smith. "Orig3n's fully-automated, high throughput laboratory and deep experience in sample collection logistics allow us to be the partner of choice for nursing homes, healthcare providers, employers, schools and other institutions nationwide." 

Orig3n's test is a validated, real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal, nasopharyngeal, anterior nasal, and mid-turbinate nasal swab specimens from individuals suspected of COVID-19.  Test results will be available in 24-36 hours from receipt of specimens in Orig3n's Boston laboratory.  For more information about the test, please visit https://orig3n.com/covid19.  More details about the offering for nursing homes can be found at:  https://orig3n.com/covid19/nursinghomes/

The Orig3n 2019 Novel Coronavirus (COVID-19) Test is made available pursuant to the "Immediately in Effect Guidance for Clinical Laboratories and Food and Drug Administration Staff", which was issued by FDA on February 29, 2020 (as subsequently modified). The EUA will be effective until the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 is terminated.  More information regarding FDA's authorization can be found FDA's website at: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd%5C). 

About Orig3n
Orig3n exists at the intersection of biological science and emerging technology, on a mission to revolutionize the future of medicine. As part of its mission to democratize access to genetic information, Orig3n provides affordable direct to consumer testing as well as physician ordered, medical grade diagnostics. Orig3n also invests in breakthrough cell therapy programs by utilizing cutting-edge cellular science to develop personalized therapies for repairing tissue damage and treating disease.  Orig3n's clinical diagnostic business provides COVID19 testing nation-wide. Since its inception in 2014, Orig3n has built the largest suite of direct-to-consumer genetic tests on the market, and the world's most comprehensive cell bank for commercial regenerative medicine applications.  For more information, visit www.orig3n.com.

SOURCE Orig3n Inc.

These press releases may also interest you

at 20:00
Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopharma...

at 16:00
As a gesture of gratitude to local public safety professionals working on the front lines of the COVID-19 pandemic, Premier Mortgage Resources, LLC, has launched a new home loan savings program, called "Hometown Heroes." Under this program, any first...

at 16:00
Burlington Medical, engineers of the highest quality and lightest weight radiation protection aprons in the industry, recently launched an advanced new core material for its Enviro-Lite® and Burlitetm products, made entirely in the U.S. The new core...

at 12:00
In lieu of an in-person update to the media, Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada's Chief Public Health Officer. "There have been 107,126 cases of COVID-19...

at 11:00
The latest data of the evolution of COVID-19 in Québec reveal 91 new cases over the past 24 hours, bringing the total number of people infected to 56,407. During the same period, 4 new deaths were recorded, to which are added 4 deaths that occurred...

at 09:58
Health Vector helps pharmaceutical companies engage with patients by supporting and empowering people along their unique life journeys. The versatile solution focuses on interventional and non-interventional studies, as well as post marketing...

News published on 12 may 2020 at 07:00 and distributed by: